By Christian Moess Laursen

 

GSK said it has received a positive opinion recommending the approval of its blood-cancer treatment momelotinib from the European Medicines Agency.

The British pharmaceutical giant said the decision on marketing authorization in the EU is expected by early 2024.

The positive opinion was adopted by the Committee for Medicinal Products for Human Use--or CHMP--of the European Medicines Agency, and is one of the final steps prior to marketing authorization decision by the European Commission.

If approved, momelotinib would be the only medicine in the EU specifically for both newly diagnosed and previously treated patients with myelofibrosis--a rare type of blood cancer--and moderate to severe anaemia, that addresses enlarged spleen and symptoms.

 

Write to Christian Moess Laursen at christian.moess@wsj.com

 

(END) Dow Jones Newswires

November 13, 2023 02:34 ET (07:34 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
過去 株価チャート
から 1 2024 まで 2 2024 Gskのチャートをもっと見るにはこちらをクリック
Gsk (LSE:GSK)
過去 株価チャート
から 2 2023 まで 2 2024 Gskのチャートをもっと見るにはこちらをクリック